Abstract: The present disclosure relates to methods of determining the amount of an anti-CD40 antibody in a sample. The present disclosure also relates to anti-CD40 antibody signature analytic peptides.

Abstract: A memory controller stores each of a plurality of data blocks encoded by error correction code (ECC) across multiple channels of a redundant memory system. Based on receiving, from the memory system, channel data of a fetch operation requesting a data block, the memory controller decodes the channel data and concurrently generates a predicted channel mark based on tests of channel-induced syndromes generated from the channel data. The predicted channel mark identifies a marked channel among the multiple channels as a likely source of data errors. The memory controller determines whether the decoding detects an uncorrectable error in the channel data and, based on determining the decoding detects an uncorrectable error in the channel data, re-reads channel data corresponding to the data block and corrects the re-read channel data by excluding, from decoding, channel data received from the marked channel.

Abstract: An apparatus and method to remove a keel strip that is centrally attached to a poultry butterfly. The butterfly has first and second poultry breasts on opposite sides of the keel strip. An elongated, longitudinally-oriented spine defines a butterfly travel path and is disposed above a longitudinally-driven conveyor. A scoring blade is disposed above, and spaced a predetermined distance from, the spine. First and second severing blades are disposed along the butterfly travel path downstream of the scoring blade with the first and second severing blades disposed on opposing first and second lateral sides of the spine. A second longitudinally-driven conveyor is disposed above the spine and ex tends from a first position downstream of the scoring blade to at least a second position between the first and second severing blades.

Abstract: An insulin infusion set (IIS) device with one or more features designed to achieve longevity in a patients continuous subcutaneous insulin infusion (CSII) site viability. One exemplary feature is an adsorbent material configured to adsorb phenolic excipients (e.g., m-cresol or other preservatives) from the insulin formulation. The adsorbent material may be positioned along a fluid pathway specifically designed to increase and/or extend exposure between the insulin formulation and the adsorbent material. Another exemplary feature is a medicament configured to reduce the patients inflammation or slow the progression of the patients inflammatory response. Yet another exemplary feature is a diffusive catheter configured to deliver the insulin formulation in a diffuse manner.

Abstract: An apparatus and method to remove a keel strip that is centrally attached to a poultry butterfly. The butterfly has first and second poultry breasts on opposite sides of the keel strip. An elongated, longitudinally-oriented spine defines a butterfly travel path and is disposed above a longitudinally-driven conveyor. A scoring blade is disposed above, and spaced a predetermined distance from, the spine. First and second severing blades are disposed along the butterfly travel path downstream of the scoring blade with the first and second severing blades disposed on opposing first and second lateral sides of the spine. A second longitudinally-driven conveyor is disposed above the spine and ex tends from a first position downstream of the scoring blade to at least a second position between the first and second severing blades.

Abstract: An insulin infusion set (IIS) device with one or more features designed to achieve longevity in a patients continuous subcutaneous insulin infusion (CSII) site viability. One exemplary feature is an adsorbent material configured to adsorb phenolic excipients (e.g., m-cresol or other preservatives) from the insulin formulation. The adsorbent material may be positioned along a fluid pathway specifically designed to increase and/or extend exposure between the insulin formulation and the adsorbent material. Another exemplary feature is a medicament configured to reduce the patients inflammation or slow the progression of the patients inflammatory response. Yet another exemplary feature is a diffusive catheter configured to deliver the insulin formulation in a diffuse manner.

Abstract: A movable Tower Inventory System which contains a number of RFID antennas mounted vertically along the tower. The Tower Inventory System is the moved along the front of storage racks to acquire information from RFID tags affixed to assets positioned on the storage rack. This information enables the determination of the x, y and z location values for each unique RFID number stored in the RFID tags.

Abstract: A movable Tower Inventory System which contains a number of RFID antennas mounted vertically along the tower. The Tower Inventory System is the moved along the front of storage racks to acquire information from RFID tags affixed to assets positioned on the storage rack. This information enables the determination of the x, y and z location values for each unique RFID number stored in the RFID tags.

Abstract: The present invention provides a method of predicting an increased likelihood of a complication associated with administration of a bone morphogenetic protein (BMP) to a subject in need of a spinal fusion surgery by detecting single nucleotide polymorphisms (SNPs) in the subject. Also provided are methods of treatment with a BMP based on the presence or absence of SNPs and kits for use in detecting the SNPs.

Abstract: A process for preparing fluorinated ethers, such as desflurane, comprises reacting the corresponding chlorinated ether, such as isoflurane, with anhydrous hydrogen fluoride in the vapor phase in the presence of chromia catalyst. It is emphasized that this abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader quickly to ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the appended issued claims.

Abstract: Processes for preparing commercial quantities of a stable, pharmaceutically acceptable sevoflurane substantially free of impurities are claimed. In another embodiment, a process for removing reactive metal salts from the surface of metallic equipment used in the distillation of sevoflurane and rendering a non-inert metallic surface of the metallic equipment inert.

Abstract: A molded article comprising sugar beet pulp is provided. In addition a method of making the such molded articles is described. Such articles are particularly useful in the packaging of food; and for medical applications where molded articles are needed.

Abstract: A moulded article comprising sugar beet pulp is provided. In addition a method of making the such moulded articles is described. Such articles are particularly useful in the packaging of food; and for medical applications where moulded articles are needed.

Abstract: An azeotrope comprising desflurane (CF3CFHOCF2H) and hydrogen fluoride (HF). The azeotrope can be prepared by fractionally distilling a crude mixture of desflurane and HF. Purer desflurane can be readily and easily separated from the azeotrope. It is emphasized that this abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader quickly to ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the appended issued claims.

Abstract: An autogyro plane (10) having a fuselage (12) with a cockpit with a pilot position (22), a tractor propeller (18) mounted at the front of the fuselage, a mast (14) projecting upwardly from the fuselage for supporting rotor blades (16), the pilot position being in front of the mast.

Abstract: Processes for preparing commercial quantities of a stable, pharmaceutically acceptable sevoflurane substantially free of impurities are claimed. In another embodiment, a process for removing reactive metal salts from the surface of metallic equipment used in the distillation of sevoflurane and rendering a non-inert metallic surface of the metallic equipment inert.

Abstract: Crude sevoflurane product comprising unacceptably high levels of HFIP can be purified by combining the crude sevoflurane product with sufficient water to produce a multiphase mixture, fractionally distilling the multiphase mixture, removing sevoflurane from the distilling multiphase mixture as an azeotrope with water, and separating substantially pure sevoflurane from the azeotrope.

Abstract: A process for purifying crude fluoromethyl 1,1,1,3,3,3-hexafluoroisopropyl ether (sevoflurane). The crude sevoflurane is repeatedly washed with water under conditions and for a time sufficient to reduce the level of 1,1,1,3,3,3-hexafluoroisopropanol (HFIP) to no more than 200 ppm or no more than 100 ppm.

Abstract: 1,1,1,3,3,3-Hexafluoroisopropanol (HFIP) substantially free of 1,1,1-trifluoroacetone (TFA) can be separated from a mixture containing both compounds by A) catalytic reduction with hydrogen followed by fractional distillation; B) cooling to a temperature at which HFIP freezes and TFA remains liquid; C) forming a high boiling complex comprising HF and TFA followed by fractional distillation; or D) producing HF-free conditions to yield a HFIP/TFA azeotrope followed by fractional distillation. It is emphasized that this abstract is provided to comply with the rules requiring an abstract, which will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. 37 CFR § 1.72(b).

Abstract: Processes for preparing commercial quantities of a stable, pharmaceutically acceptable sevoflurane substantially tree of impurities are claimed. In another embodiment, a process for removing reactive metal, salts from the surface of metallic equipment used in the distillation of sevoflurane and rendering a non-inert metallic surface of the metallic equipment inert.